Clinical trials: psoriasis
Arthritis, Rheumatoid, Spondylarthritis
Follow-up of Person-centered Care of Young Adults With Rheumatic Disease
The purpose of the study is to study how a person-centered structured team caretaking of young adults (16-23 years) with newly diagnosed rheumatoid arthritis (RA), spondartrit (SpA) and psoriasartrit (PsA) in routine clinical…
- Conditions
- Arthritis, Rheumatoid, Spondylarthritis, Arthritis, Psoriatic
- Trial name
- NCT02402894
- Testing
- no intervention
- Where
- Sweden
- Volunteers
- 74 people
- Sponsor
- Vastra Gotaland Region
Rheumatoid Arthritis, Ankylosing Spondylitis
Employment and Arthritis: Making it Work
The investigators plan to conduct a randomized controlled trial to evaluate the effectiveness and the cost effectiveness of an on-line eLearning program (entitled Employment and Arthritis: Making it Work) designed to help people…
- Conditions
- Rheumatoid Arthritis, Ankylosing Spondylitis, Lupus Erythematosus, Systemic, Psoriatic Arthritis
- Trial name
- MIW (NCT01852851)
- Testing
- Employment and Arthritis: Making it Work
- Where
- Canada
- Volunteers
- 528 people
- Sponsor
- University of British Columbia
Plaque Psoriasis
Efficacy and Safety of Namilumab (MT203) for Plaque Psoriasis
The purpose of this study is to establish proof of efficacy for namilumab in moderate to severe plaque psoriasis, measured as Psoriasis Area and Severity Index (PASI)75 response rate at Week 12.
- Trial name
- NCT02129777
- Testing
- Namilumab
- Where
- 10 sites in Canada
- Volunteers
- 122 people
- Sponsor
- Takeda
Psoriasis
An Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Genital Psoriasis
This Phase 3 multicenter, randomized, placebo-controlled, double-blind study is designed to evaluate the efficacy and safety of apremilast in subjects with moderate to severe genital psoriasis (modified sPGA-G ≥3, moderate or…
- Trial name
- DISCREET (NCT03777436)
- Testing
- Apremilast
- Where
- 52 sites in United States, Belgium and 5 more
- Volunteers
- 289 people
- Sponsor
- Amgen
Adult Non-infectious Uveitis
A Multicenter, Open-label Study on the Efficacy and Safety of Tebiovio® (Adalimumab) in Treating Chinese Children With Severe Plaque Psoriasis
This study is a real-world clinical research on adalimumab. The project plans to enroll 30 subjects. The safety and efficacy of adalimumab injection for adult non-infectious uveitis are being investigated.
- Trial name
- NCT07663331
- Testing
- TyboWe® Adalimumab Injection
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Plaque Psoriasis
A Study of the Safety and Efficacy of Risankizumab in Adult Participants With Plaque Psoriasis Who Have Had a Suboptimal Response to Secukinumab or Ixekizumab
This study will evaluate whether adult participants with moderate to severe plaque psoriasis who have been treated with secukinumab or ixekizumab for at least 6 months and are experiencing a suboptimal response may benefit from…
- Trial name
- NCT04102007
- Testing
- Risankizumab
- Where
- 57 sites in United States, Australia and 6 more
- Volunteers
- 244 people
- Sponsor
- AbbVie
Psoriasis
A Study to Evaluate Efficacy and Safety of SAR441566 in Adults With Plaque Psoriasis
This was a Phase 2, international, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, 12-week study. It was designed to assess the therapeutic dose, efficacy, and safety of treatment with SAR441566 in male…
- Trial name
- SPECIFI-PSO (NCT06073119)
- Testing
- SAR441566
- Where
- 51 sites in United States, Argentina and 15 more
- Volunteers
- 221 people
- Sponsor
- Sanofi
Psoriasis
LTS of Siliq vs. Other Therapies Treating of Adults With Moderate-to-Severe Psoriasis
Prospective, Observational Study to Assess the Long-Term Safety of Brodalumab Compared with Other Therapies in the Treatment of Adults with Moderate-to-Severe Psoriasis
- Trial name
- NCT03254667
- Testing
- Brodalumab, Comparator Drug (non-biologic IL-17 inhibitors)
- Where
- United States
- Volunteers
- 3,500 people
- Sponsor
- Bausch Health Americas, Inc.
Psoriasis Vulgaris
LP0058-1005 - A Open-Label, Four-Way Crossover and Food-Effect Study of LEO 32731 in Healthy Subjects
LEO 32731 ("Study Drug") is an investigational drug which is being developed by LEO Pharma A/S ("the Sponsor"), with an aim to help people with skin conditions called psoriasis.
- Trial name
- NCT02126371
- Testing
- LEO32731
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- LEO Pharma
Psoriasis, Metabolic Syndrome
Peds Metabolic Syndrome in Psoriasis
The objective of this study is to assess whether there is an increased risk of the metabolic syndrome in children with psoriasis compared to children without psoriasis.
- Trial name
- NCT00930592
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Tufts Medical Center
Arthritis, Psoriatic
A Study to Evaluate the Use of Apremilast in Patients With Psoriatic Arthritis, Naïve to Biological Treatment
Observational, prospective and multicenter study in approximately 25 sites nationwide. The investigators participating in this study will be rheumatologists specializing in this pathology.
- Trial name
- PREVAIL (NCT03828045)
- Testing
- Apremilast
- Where
- 20 sites in Spain
- Volunteers
- 119 people
- Sponsor
- Amgen
Plaque Psoriasis
Long-Term Treatment Effect With Tildrakizumab in Participants With Plaque Psoriasis
The purpose of this study is to evaluate the psoriasis disease control over time in participants who had received Tildrakizumab for at least the last 5 years and have discontinued it and to describe blood and skin inflammatory…
- Trial name
- MODIFY (NCT04339595)
- Testing
- Tildrakizumab
- Where
- 3 sites in Poland
- Volunteers
- 47 people
- Sponsor
- Almirall, S.A.
Psoriatic Arthritis
Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Have an Inadequate Response or Are Intolerant to Biologic DMARD Therapy
The primary objective of this study is to evaluate the effect of filgotinib compared to placebo as assessed by the American College of Rheumatology 20% improvement (ACR20) response in participants with active psoriatic arthritis…
- Trial name
- PENGUIN 2 (NCT04115839)
- Testing
- Filgotinib
- Where
- 59 sites in United States, Australia and 9 more
- Volunteers
- 106 people
- Sponsor
- Gilead Sciences
Palmoplantar Pustulosis
Phase 3, Randomized Study of Apremilast in Japanese Participants With Palmoplantar Pustulosis (PPP)
The primary objective of the study is to evaluate the efficacy of apremilast (AMG 407) twice daily (BID) compared with placebo in participants with Palmoplantar Pustulosis (PPP).
- Trial name
- NCT05174065
- Testing
- Apremilast
- Where
- 40 sites in Japan
- Volunteers
- 176 people
- Sponsor
- Amgen
Psoriasis
Study to Assess the Safety and Tolerability of PBF-1650 in Healthy Volunteers.
Single center, randomized, double-blind, placebo-controlled clinical study to assess the safety and tolerability of PBF-1650 in order to obtain the Maximum Tolerated Dose (MTD).
- Trial name
- ADENOIMMUNE (NCT03798236)
- Testing
- PBF-1650 oral capsules
- Where
- Spain
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Palobiofarma SL
Psoriasis Vulgaris With Metabolic Disorders
Metformin for Treatment of Psoriasis Combined With Disorders of Glucose and Lipid Metabolism
Psoriasis and metabolic disorders are well-known mutual comorbidities. The investigators hypothesized metformin can ameliorate both psoriasis and metabolic disorders mainly via gut microbiota modulation.
- Trial name
- MPGLM (NCT03629639)
- Testing
- Metformin
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Central South University
Psoriasis
A Study to Assess the Efficacy and Safety of XP23829 in Subjects With Moderate-to-Severe Chronic Plaque-Type Psoriasis
The study objectives are the following: 1. To evaluate the efficacy of 3 doses of XP23829 compared to placebo for the treatment of moderate-to-severe chronic plaque-type psoriasis. 2.
- Trial name
- NCT02173301
- Testing
- XP23829 400 mg QD, XP 23829 800 mg QD, XP23829 400 mg BID
- Where
- 31 sites in United States
- Volunteers
- 200 people
- Sponsor
- Dr. Reddy's Laboratories Limited
Psoriasis Vulgaris
Efficacy and Safety of Calcipotriol Plus Hydrocortisone Ointment Compared With Tacalcitol Ointment in Patients With Psoriasis on the Face and Skin Folds
There are few therapies suitable for the treatment of psoriasis on the face and skin folds. As these areas are sensitive, irritation and other adverse reactions are more common than elsewhere on the body.
- Trial name
- NCT00640822
- Testing
- Calcipotriol plus hydrocortisone ointment vehicle, Tacalcitol Ointment, Calcipotriol plus hydrocortisone ointment
- Where
- 3 sites in Canada, France and 1 more
- Volunteers
- 782 people
- Sponsor
- LEO Pharma
Rheumatoid Arthritis, Polyarthritis
Construct Validity and Responsiveness of EQ-5D-3L in Patients With Rheumatic Disease
The aim of this study is to investigate the construct validity (convergent and known-groups) and responsiveness of EQ-5D-3L in patients with rheumatoid arthritis, polyarthritis, psoriatic arthritis, and ankylosing spondylitis.
- Conditions
- Rheumatoid Arthritis, Polyarthritis, Psoriatic Arthritis, Ankylosing Spondylitis
- Trial name
- NCT06568029
- Testing
- Questionnaire
- Where
- Sweden
- Volunteers
- 77,651 people
- Sponsor
- Karolinska Institutet
Psoriatic Arthritis, Psoriasis
HIPPOCRATES Prospective Observational Study
HIPPOCRATES is an Innovative Medicines Initiative (IMI) funded EU Consortium established to address key unmet clinical needs in psoriatic disease.
- Trial name
- HPOS (NCT05858528)
- Testing
- PEST screening questionnaire
- Where
- United Kingdom
- Volunteers
- 25,000 people
- Sponsor
- University of Oxford
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.